Clinical trials: Sunitinib, completed
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma, Liver Cancer
SU011248 in Advanced Hepatocellular Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer.
- Trial name
- NCT00361309
- Testing
- SU011248
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Phase I;To investigate the clinically recommended dose of Sunitinib malate (SU011248) following multiple oral dosing in the first cycle (4 consecutive weeks and 2 weeks rest) by reviewing the safety and tolerability.
- Trial name
- NCT00457743
- Testing
- Sunitinib malate (SU011248)
- Where
- 4 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Pfizer
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Renal Cell Carcinoma
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
This study is to evaluate the efficacy, safety, and feasibility of sunitinib in 4/2 and 2/1 regimen in previously untreated metastatic RCC to select the most promising regimen, which should be used in further studies of this…
- Trial name
- NCT00570882
- Testing
- Sunitinib 2/1, Sunitinib 4/2
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Asan Medical Center
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
- Trial name
- NCT03249740
- Testing
- GB-102, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Graybug Vision
Kidney Cancer
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541008
- Testing
- sunitinib malate
- Where
- 22 sites in France
- Volunteers
- 92 people
- Sponsor
- UNICANCER
Adrenocortical Carcinoma
Sunitinib in Refractory Adrenocortical Carcinoma
Although a first randomized trial in patients with advanced ACC leading to the establishment of a first line cytotoxic chemotherapy is ongoing (FIRM-ACT), the failure rate even of this FIRM-ACT study is most likely clearly above…
- Trial name
- SIRAC (NCT00453895)
- Testing
- Sunitinib
- Where
- 2 sites in Germany
- Volunteers
- 39 people
- Sponsor
- University of Wuerzburg
Metastatic Renal Cell Carcinoma
Testosterone in Metastatic Renal Cell Carcinoma Patients
Purpose To determine efficacy and safety of Testosterone in male patients with metastatic renal cell carcinoma and fatigue receiving targeted therapy or checkpoint inhibitors.
- Trial name
- FARETES (NCT03379012)
- Testing
- Testosterone undecanoate and sunitinib or pazopanib
- Where
- 4 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Kidney Cancer Research Bureau
Kidney Cancer
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in…
- Trial name
- NCT00498966
- Testing
- Perifosine
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- AEterna Zentaris
Renal Cell Cancer, Colorectal Cancer
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
The purpose of this study is to assess the influence of Sunitinib and Sorafenib on fatigue, quality of life and depression in patients with metastatic renal cell or colorectal cancer or GIST.
- Conditions
- Renal Cell Cancer, Colorectal Cancer, GIST
- Trial name
- NCT00979329
- Testing
- Questionnaires
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before.
- Trial name
- SUNIKA (NCT00460798)
- Testing
- Sutent: observational study
- Volunteers
- 356 people
- Sponsor
- Pfizer
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
- Trial name
- NCT00451048
- Testing
- sunitinib malate
- Where
- 4 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Prostate Cancer
Study of SU11248 in Men With Advanced Prostate Cancer
There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
- Trial name
- NCT00299741
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Kidney Cancer, Metastatic Cancer
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00814021
- Testing
- sunitinib malate
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Claudius Regaud
Refractory Solid Tumors
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following…
- Trial name
- NCT02691793
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing…
- Trial name
- NCT00372424
- Testing
- Herceptin, Sunitinib, Taxotere
- Where
- 7 sites in Belgium, Italy
- Volunteers
- 26 people
- Sponsor
- Pfizer